NCCM
CYTK icon

Nine Chapters Capital Management’s Cytokinetics CYTK Stock Holding History

Nine Chapters Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-20,600
Closed -$265K – 84
2017
Q1 		$265K Buy
+20,600
New +$241K 0.36% 123
2015
Q4 		– Sell
-89,100
Closed -$596K – 148
2015
Q3 		$596K Sell
89,100
-10,200
-10% -$69.6K 0.05% 509
2015
Q2 		$667K Sell
99,300
-75,400
-43% -$494K 0.06% 469
2015
Q1 		$1.18M Buy
174,700
+114,700
+191% +$857K 0.1% 324
2014
Q4 		$481K Buy
60,000
+8,400
+16% +$36K 0.04% 551
2014
Q3 		$182K Buy
+51,600
New +$217K 0.02% 866

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Nine Chapters Capital Management's CYTK Position: Q2 2017 in Review

Nine Chapters Capital Management sold out of Cytokinetics (CYTK) in Q2 2017, closing a stake of 20,600 shares — an estimated $265K sold.

Nine Chapters Capital Management first reported a position in CYTK in Q3 2014 and held it in 6 quarters. The position peaked at $1.18M in Q1 2015. 136 funds tracked by Wall St. Rank hold CYTK as of Q2 2017.

  • Nine Chapters Capital Management reported no remaining Cytokinetics position as of Q2 2017 after selling out during the quarter.
  • Nine Chapters Capital Management sold 20,600 Cytokinetics shares in Q2 2017, an estimated $265K.
  • Nine Chapters Capital Management first reported a position in Cytokinetics in Q3 2014 and held it in 6 quarters.
  • Nine Chapters Capital Management's Cytokinetics position peaked at $1.18M in Q1 2015.
  • 136 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2017.

Based on Nine Chapters Capital Management's 13F filing for Q2 2017, filed 31 Jul 2017.